ABBV shares consolidate near $225 with MACD signaling caution at recent highs: weekly forecast

Traders Union
All News
Financial News
AbbVie slips 0.78% over the week

Highlights

AbbVie trades above major weekly moving averages, indicating sustained medium- and long-term bullish momentum.
Mixed momentum signals and overbought oscillator readings suggest the stock faces risk of near-term consolidation or correction.
Expected weekly price corridor is $217.50 to $233.50, with roughly equal probabilities of a breakout or deeper pullback.

Earnings upgrades and pipeline progress drive positive weekly sentiment

AbbVie delivered strong first-quarter earnings and raised its full-year profit forecasts, providing a boost to overall sentiment. The company has also secured several European regulatory approvals and shared positive updates on its oncology pipeline, with 21 studies to be presented at the 2026 European Hematology Association Congress covering key therapies such as epcoritamab and venetoclax. Alongside this, ABBV continues to expand its pipeline through research collaborations and maintains a robust record of dividend growth, currently offering a forward dividend yield of around 3%.

Overbought signals as technicals indicate pause near weekly highs

On the weekly timeframe, ABBV remains positioned above its MA-20 and MA-50, which now act as dynamic support, with the MA-200 further below at $177.89. Key support is seen at the MA-20 ($216.06), while resistance is projected near $233.50. Weekly volatility stands at 10.25%. Weekly indicators send mixed signals: the W1 MACD generates a strong sell reading, while the ADX trend is neutral. The RSI and CCI suggest continued buying interest, but both the Stochastic RSI and Bull/Bear Power indicate overbought conditions. The Awesome Oscillator remains neutral. These signals, together with a shallow weekly decline, reflect a pause near highs with a potential for correction or sideways movement.

Consolidation expected as overbought risks temper bullish outlook

For the next five trading days, ABBV is expected to trade between $217.50 and $233.50 based on weekly volatility and indicator readings. Momentum remains neutral to bullish, but overbought signals from short-term oscillators indicate risk of a near-term pullback. The most likely scenario is consolidation above the MA-20 as bulls and bears reach a standoff. A breakout above $233.50 could accelerate gains if buying resumes, while a drop below $217.50 would likely trigger deeper correction as short-term sentiment turns more cautious.

Earlier, analysts noted that AbbVie's stock was experiencing strong upward momentum supported by positive drug approvals and technical trends. The current action reinforces this constructive outlook but highlights an emerging risk of a near-term pullback, with $217.50 and $233.50 serving as the immediate levels to watch for a decisive move.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.